TrialOncoimmunology2021

Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies.

Si-Cong Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.